CUSIP: 68234L207
Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
4,482,667
-
Share change
-
+2,526,495
-
Total reported value
-
$7,286,000
-
Price per share
-
$1.63
-
Number of holders
-
29
-
Value change
-
+$4,179,836
-
Number of buys
-
20
-
Number of sells
-
5
Quarterly Holders Quick Answers
What is CUSIP 68234L207?
CUSIP 68234L207 identifies ONCS - ONCOSEC MED INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2018
-
Previous quarter:
Q3 2017
Recent filing periods for CUSIP 68234L207:
Institutional Holders of ONCOSEC MED INC - COM NEW (ONCS) as of Q4 2017
As of 31 Dec 2017,
ONCOSEC MED INC - COM NEW (ONCS) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,482,667 shares.
The largest 10 holders included
Point72 Asset Management, L.P., Vanguard Group Inc, Crawford Lake Capital Management, LLC, RENAISSANCE TECHNOLOGIES LLC, DEUTSCHE BANK AG\, SABBY MANAGEMENT, LLC, J. Goldman & Co LP, PRICE T ROWE ASSOCIATES INC /MD/, Zurcher Kantonalbank (Zurich Cantonalbank), and MYDA Advisors LLC.
This page lists
29
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.